---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031478"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:54:45.327225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q4 2023 net loss of $7.6M and cash of $21.3M; highlights positive clinical data

## Summary
- Q4 2023 net loss $7.6M ($0.22 per share) vs Q4 2022 net loss $7.8M ($0.32 per share).
- Full-year 2023 net loss $30.0M ($1.00 per share); R&D expenses increased to $16.8M.
- Cash $21.3M as of Dec 31, 2023 vs $18.2M a year earlier; private placement extended runway into 1Q 2025.
- 100% of evaluable leukemia patients (n=10) in INB-100 Phase 1 remained in remission as of Nov 3, 2023.
- Appointed Dr. Corinne Epperly, M.D., M.P.H. to Board of Directors.

## SEC filing metadata
- accession: 0000950170-24-031478
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/0000950170-24-031478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/inab-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031478
- JSON: https://secwatch.observer/filing/0000950170-24-031478.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031478.txt

## Key facts
- Earnings Releases
  IN8BIO, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the three months ended December 31, 2023, EPS $0.22 per basic and diluted common share.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Net income: a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the three months ended December 31, 2023
  - EPS: $0.22 per basic and diluted common share
  - Result: reported results
  source text: IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/0000950170-24-031478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.